Circuit lifetime with citrate versus heparin in pediatric continuous venovenous hemodialysis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F16%3AE0105564" target="_blank" >RIV/00843989:_____/16:E0105564 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1097/PCC.0000000000000860" target="_blank" >http://dx.doi.org/10.1097/PCC.0000000000000860</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/PCC.0000000000000860" target="_blank" >10.1097/PCC.0000000000000860</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Circuit lifetime with citrate versus heparin in pediatric continuous venovenous hemodialysis

Popis výsledku v původním jazyce

OBJECTIVES: To determine if there is a difference between regional citrate and global heparinized anticoagulation on circuit lifetimes during continuous venovenous hemodialysis in children. DESIGN: Prospective "cross-over" trial. SETTING: PICU, Department of Pediatrics, University Hospital Ostrava. PATIENTS: Children 0-18 years old. INTERVENTIONS: From 2009 to 2014, 63 eligible children (age, 89.24?±?62.9 mo; weight, 30.37?±?20.62?kg) received at least 24 hours of continuous venovenous hemodialysis. Each child received four continuous venovenous hemodialysis circuits with anticoagulants in the following order: heparin, citrate, heparin, citrate. Circuit life ended when transmembrane pressure was greater than or equal to 250?mm Hg for more than 60 minutes. MEASUREMENTS AND MAIN RESULTS: The total mean circuit lifetime was 39.75?±?10.73 hours. Citrate had a significantly longer median circuit lifetime (41.0?hr; CI, 37.6-44.4) than heparin (36.0?hr; CI, 35.4-36.6; p = 0.0001). Mortality was 33.33%. Circuit lifetime was significantly correlated to patient age (r = 0.606), weight (r = 0.763), and blood flow rate (r = 0.697). Transfusion rates (units of red cells per circuit of continuous venovenous hemodialysis) were 0.17 (0.0-1.0) with citrate and 0.36 (0.0-2.0) with heparin (p = 0.002). CONCLUSIONS: We showed in our study that citrate provided significantly longer circuit lifetimes than heparin for continuous venovenous hemodialysis in children. Citrate was superior to heparin for the transfusion requirements. Citrate was feasible and safe in children and infants.

Název v anglickém jazyce

Circuit lifetime with citrate versus heparin in pediatric continuous venovenous hemodialysis

Popis výsledku anglicky

OBJECTIVES: To determine if there is a difference between regional citrate and global heparinized anticoagulation on circuit lifetimes during continuous venovenous hemodialysis in children. DESIGN: Prospective "cross-over" trial. SETTING: PICU, Department of Pediatrics, University Hospital Ostrava. PATIENTS: Children 0-18 years old. INTERVENTIONS: From 2009 to 2014, 63 eligible children (age, 89.24?±?62.9 mo; weight, 30.37?±?20.62?kg) received at least 24 hours of continuous venovenous hemodialysis. Each child received four continuous venovenous hemodialysis circuits with anticoagulants in the following order: heparin, citrate, heparin, citrate. Circuit life ended when transmembrane pressure was greater than or equal to 250?mm Hg for more than 60 minutes. MEASUREMENTS AND MAIN RESULTS: The total mean circuit lifetime was 39.75?±?10.73 hours. Citrate had a significantly longer median circuit lifetime (41.0?hr; CI, 37.6-44.4) than heparin (36.0?hr; CI, 35.4-36.6; p = 0.0001). Mortality was 33.33%. Circuit lifetime was significantly correlated to patient age (r = 0.606), weight (r = 0.763), and blood flow rate (r = 0.697). Transfusion rates (units of red cells per circuit of continuous venovenous hemodialysis) were 0.17 (0.0-1.0) with citrate and 0.36 (0.0-2.0) with heparin (p = 0.002). CONCLUSIONS: We showed in our study that citrate provided significantly longer circuit lifetimes than heparin for continuous venovenous hemodialysis in children. Citrate was superior to heparin for the transfusion requirements. Citrate was feasible and safe in children and infants.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FG - Pediatrie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pediatric critical care medicine

ISSN

1947-3893

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

n. 9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

"e399"-"e405"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—